Company intelligence / Profile preview

Livionex

Los Gatos, California, United Stateslivionex.com ↗

Ownership: Private
Development stage: Commercial

Overview

Livionex has reported positive end-of-phase 2 results with its C-KAD eye drop for early-to-moderate cataracts and is preparing to advance to Phase 3 trials. Its LIVFRESH toothpaste is approved in Europe and commercially available. The company’s technology platform targets metal ions implicated in disease pathways such as oxidative stress and inflammation. Other programs are at preclinical or early clinical stages.

Therapeutic areas: OtherOphthalmologyCardiovascularInfectious Diseases
Modalities: Small moleculeDevice (for oral care products/toothpaste)
Industry: Biotech

Drug pipeline

5 assets

Livionex CVI Topical Treatment

4 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with major US universities; specific partners not named publiclyNo major pharma partnerships disclosed.

Beyond the preview

Go deeper on Livionex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Livionex.

Explore the full profile